1
|
Dooley CM, Devocelle M, McLoughlin B, Nolan KB, Fitzgerald DJ, Sharkey CT. A novel family of hydroxamate-based acylating inhibitors of cyclooxygenase. Mol Pharmacol 2003; 63:450-5. [PMID: 12527817 DOI: 10.1124/mol.63.2.450] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Aspirin irreversibly inhibits cyclooxygenase (COX) by acetylating a serine residue in the active site. We synthesized a series of novel acylating agents based on our previously reported acetylating compound, O-acetylsalicylhydroxamic acid. One of these, triacetylsalicylhydroxamic acid (TriAcSHA) was more effective than aspirin and O-acetylsalicylhydroxamic acid in inactivating both COX-1 and COX-2. Preincubation of COX-1 with inhibitor for 5 min yielded IC(50) values of 18 microM for TriAcSHA and 60 microM for acetylsalicylic acid. Inhibition was time-dependent, with complete inhibition within 10 min at a concentration of 50 microM. As with aspirin, mutation of the serine 530 of COX-1 to alanine abolished the activity of the TriAcSHA. Mutation of the alanine 119 to a glutamine markedly reduced the sensitivity to TriAcSHA, suggesting that this residue was necessary for the interaction with the enzyme. TriAcSHA was also more effective than aspirin as an inhibitor of platelet aggregation induced by arachidonic acid. The diacetylated phenylhydroxamates N-methyl-O,O-diacetylsalicylhydroxamic acid, N,O-diacetylbenzohydroxamic acid, and 2-methyl-O,N-diacetylbenzohydroxamic acid showed reduced or absent activity against COX-1. In addition, we synthesized a series of triacylsalicylhydroxamic acids with progressively longer acyl groups (three to six carbons). All of the compounds inhibited COX-1 and demonstrated progressively greater COX-1 selectivity with increasing number of carbons. Hence, salicylhydroxamic acid provides a versatile backbone for the generation of a family of acylating inhibitors of cyclooxygenase.
Collapse
Affiliation(s)
- C M Dooley
- Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland
| | | | | | | | | | | |
Collapse
|
5
|
Jolley JN, Yanovsky AI, Kelland LR, Nolan KB. Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Crystal and molecular structure of [PtL4CL2].H20 where L4 is ethylenediamine-N,N'-diacetate. J Inorg Biochem 2001; 83:91-100. [PMID: 11237267 DOI: 10.1016/s0162-0134(00)00190-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Several cisplatin analogues of ethylenediamine-derived ligands containing alcohol, carboxylic acid and acetate substituents have been prepared and characterised. Oxidation of some of these square planar platinum(II) complexes using aqueous hydrogen peroxide gave octahedral platinum(IV) complexes, containing trans hydroxo ligands. Acetylation of the hydroxo ligands was achieved by reaction with acetic anhydride, giving complexes which are analogues of the antitumour drug, JM-216. Oxidation of the complex [Pt(H2L4)Cl2], where H2L4 is ethylenediamine-N,N'-diacetic acid, with H2O2 gave the platinum(IV) complex [PtL4Cl2].H2O in which L4 is tetradentate as shown by a crystal and molecular structure. This complex was previously reported to be [Pt(HL4)(OH)Cl2] in which HL4 is tridentate. Several of the complexes were tested for antitumour activity against five human ovarian carcinoma cell lines. IC50 values range from 4.0 microM for cis,trans-PtCl2(OH)2(NH2CH2CH2NHCH2CH2OH) against the CH1 cell line to >25 microM indicating moderate to low activity relative to other platinum complexes.
Collapse
Affiliation(s)
- J N Jolley
- Department of Chemistry, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin
| | | | | | | |
Collapse
|
10
|
Moriarty M, Maher M, Morton G, Flavin A, Mooney E, Neilan J, Nestor P, Horgan PG, Kerin M, Waldron D, Gannon F, Given H, McCann AH, Dervan PA, Codd MB, Guillick WJ, Carney DN, Horgan PG, O’Brien DP, Waldron DJ, Mooney E, McGuire M, Given HF, Dolan J, O’Hora A, Droogan O, Curran B, Henry K, Leader M, Meehan S, Magee H, Carney D, Dervan P, Lawler M, McCann SR, Humphries P, Barrett J, O’Sullivan G, Collins JK, Williams N, Daly J, Herlyn M, Corbally N, Sweeney E, Dervan P, Carney DN, Sheppard MN, Hamid Q, Corrin B, Weedle RM, Cotter TG, Wilkinson YA, McKenna PG, Hahnvajanawong C, O’Sullivan G, McCarthy M, Collins JK, Atkinson RJ, Pedlow P, McQuaid S, Johnson P, Stuart J, O’Meara A, Russell SEH, White PM, Atkinson RJ, Hickey GI, Pomeroy M, Prosser E, Barker F, Casey M, Carroll K, O’Kennedy R, Duffy G, Fennelly JJ, Duffy MJ, Reilly D, Fennelly JJ, O’Higgins N, Rochfort H, O’Neal KL, Hoper M, Odling-Smee GW, Abram WP, McKenna PG, Mooney E, Brougham C, Horgan P, Waldron D, O’Brien D, Kerin M, Heyden DR, Given HF, Lanigan D, McLean P, Murphy D, Donovan MG, Curran B, Leader M, Martin A, Clynes M, Graham D, Curran B, McQuaid S, Dorman T, Breathnach F, Fitzgerald RJ, Leader M, O’Meara A, Lennon SV, Martin SJ, Cotter TG, Ryan L, Kilfeather SA, O’Malley K, Nolan KB, Croke DT, Helene C, Browne PV, Lawler M, McCann SR, Clarke E, McCann SR, Glynn J, Cotter K, Shine M, Cotter T, Sweeney E, Dervan P, Carney DN, McKelvey VJ, Stefani LAJ, McKenna PG, Ranjbar S, Cromie E, Eason S, Hannigan BM, Corbett A, O’Sullivan G, Collins JK, O’Brien F, O’Sullivan G, Collins JK, Carney DN, Grogan L, Leonard N, Morton G, Flavin A, Moriarty M, Foley-Nolan D, McCann A, Carney DN, Fennelly JJ, Jones M, Garrett C, Pomeroy M, Brennan DP, Powell D. Irish association for cancer research. Ir J Med Sci 1991. [DOI: 10.1007/bf02947640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|